Tata Mid Cap Fund
The scheme seeks to provide income distribution and / or medium to long term capital gains. Investment would be focussed towards mid cap stocks.
Growthvine rating: 3/5 — ranked #13 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹415.97 (as of 2026-10-23) |
|---|
| AUM | ₹5,860 Cr |
|---|
| Expense ratio | 1.56% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Satish Chandra Mishra |
|---|
| Exit load | 0.5% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 12.65% |
|---|
| Sharpe ratio | 0.43 |
|---|
| Standard deviation | 16.93% |
|---|
| Max drawdown | −68.28% |
|---|
| Alpha | -0.73 |
|---|
| Beta | 0.91 |
|---|
Over 5 years, captured 85.4% of NIFTY Midcap 150's upside and 85.6% of its downside.
Market cap allocation
| Large cap | 16.9% |
|---|
| Mid cap | 76.5% |
|---|
| Small cap | 6.6% |
|---|
Concentration
| Top 5 holdings | 15.7% |
|---|
| Top 10 holdings | 29.8% |
|---|
| Total holdings | 58 |
|---|
| Index overlap | 36.5% |
|---|
| Active share | 63.5% |
|---|
Top holdings
- Mankind Pharma Limited — 3.4%
- Bharat Heavy Electricals Ltd. — 3.2%
- One 97 Communications Limited — 3.2%
- Multi Commodity Exchange of India Ltd — 3.0%
- L&T Finance Limited — 2.9%
- AU Small Finance Bank Limited — 2.9%
- IndusInd Bank Ltd. — 2.9%
- Max Financial Services Limited — 2.8%
- Max Healthcare Institute Limited — 2.8%
- Federal Bank Ltd. — 2.7%
Top sectors
- Banking & Financial — 17.1%
- Pharma & Biotech — 9.9%
- Automobile — 9.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −7.8% | Q4 (Bottom) | #29 of 31 |
| 2025 | 5.8% | Q1 (Top) | #5 of 29 |
| 2024 | 22.7% | Q3 | #22 of 29 |
| 2023 | 40.5% | Q2 | #8 of 28 |
| 2022 | 0.6% | Q3 | #14 of 22 |